Best Doctors competitors

Best Doctors Competitors include Evidation Health, OncoCyte, hVIVO and Immucor.
Add company...
Best Doctors
Best Doctors
Works with leading doctors to find the right diagnosis and right treatment for 30 million members in every major region of the world. It also designs and implements international insurance programs that help people worldwide be sure they get the right care.
Evidation Health
Evidation Health
Helping partners quantify and optimize health outcomes through advanced analytics of medical, behavioral and contextual data at the patient-consumer level.
OncoCyte
OncoCyte
OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.
hVIVO
hVIVO
hVIVO plc is the name of our LSE AIM-listed business, which was re-named and re-branded from Retroscreen Virology Group plc.
Immucor
Immucor
A global leader in transfusion and transplantation diagnostics.
Founding Date
Founding Date
1989
Founding Date
2014
Founding Date
N/A
Founding Date
1998
Founding Date
1982
Type
Type
Private
Type
Private
Type
Public
Type
Public
Type
Private
Tags
Locations
Locations
Quincy, US HQ
Melbourne, AU
Toronto, CA
Rotterdam, NL
Lisboa, PT
Madrid, ES
London, GB
see more
Locations
Menlo Park, US HQ
Locations
Alameda, US HQ
Locations
London, GB HQ
Locations
Norcross, US HQ
Employees
Employees
9521% decrease
Employees
1141% decrease
Employees
16
Employees
25519% decrease
Employees
956
Valuation ($)
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
156.7 m
Valuation ($)
57.1 m
Valuation ($)
N/A
Twitter followers
Twitter followers
7.8 k
Twitter followers
1.6 k
Twitter followers
N/A
Twitter followers
422
Twitter followers
160

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
£11.9m (FY, 2017)
Revenue (est.)
$380m (FY, 2016)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
£8.1m (FY, 2017)
Cost of goods
$144m (FY, 2016)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Gross profit
£3.8m (FY, 2017)
Gross profit
$236m (FY, 2016)
Net income
Net income
N/A
Net income
N/A
Net income
($19.4m) (FY, 2017)
Net income
(£9.5m) (FY, 2017)
Net income
($43.8m) (FY, 2016)

Funding

Latest funding round
Latest funding round
$ 45.5m (over 6 years ago)
Latest funding round
$ 30m (7 months ago)
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
N/A
Total funding raised
Total funding raised
$ 65.5m
Total funding raised
$ 61m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

Evidation Health
HQ
Menlo Park, US
Employees
114↓ 1% decrease

Helping partners quantify and optimize health outcomes through advanced analytics of medical, behavioral and contextual data at the patient-consumer level.

View company
OncoCyte
HQ
Alameda, US
Employees
16

OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.

View company
hVIVO
HQ
London, GB
Employees
255↓ 19% decrease

hVIVO plc is the name of our LSE AIM-listed business, which was re-named and re-branded from Retroscreen Virology Group plc.

View company
Immucor
HQ
Norcross, US
Employees
956

A global leader in transfusion and transplantation diagnostics.

View company